Eli Lilly and Company

Novo Nordisk A/s

Other

Kabushiki Kaisha Kobe Seiko Sho

Japan Lsi Co., Ltd.

Charles Howard Mitch

John S Ward

Per Sauerberg

Preben H Olesen

Harlan E Shannon

Dennis Michael Zimmerman

Leander Merritt

Roger L Robey

Charles A Alt

Concepcion Pedregal-Tercero

Nuria Diaz Buezo

Gary A Rhodes

Eldon E Van Meter

Steven James Quimby

Franklin P Bymaster

Paul Leslie Ornstein

Marta Garcia De La Torre

Kumiko Takeuchi

Philip Floyd Hughes

Bret E Huff

Darryle D Schoepp

Sean Patrick Hollinshead

Miles Goodman Siegel

Michael A Staszak

Loretta A McQuaid

Jose Serafin Mendoza

Joseph Wendell Wilson

Mark Donald Chappell

Tatiana Natali Vetman

Edward C Smith

David Lee McKinzie

Jon Kevin Reel

Bruce Anthony Dressman

Russell Dean Stucky

Celia A Whitesitt

Prabhakar Kondaji Jadhav

Maria-Jesus Blanco-Pillado

Renhua Li

Dana Rae Benesh

William Glen Holloway

Eric George Tromiczak

Chad Nolan Wolfe

Adam Michael Fivush

Maria Jesus Blanco-Pillado

Howard Barff Broughton

James Edward Matt

Stephon Cornell Smith

Elizabeth Marie Thomas

Michael Angelo Statnick

Dana Rae Smith

James Erwin Fritz

David Lee Mckinzie

James Edward Junior Matt

Concepcion Lilly S A Pedregal Tercero

Garcia Marta Lilly S A De La Torre

Nuria Lilly S A Diaz Buezo

Marta Garcia Lilly SA De La Torre

A mGlu2/3 receptor antagonist of the formula: its uses, and methods for its preparation are described.

4-substituted-3-benzyloxy-bicyclo[3.1.0]hexane compounds as mGluR 2/3 antagonists

4-substituted-3-phenylsulfanylmethyl-bicyclo[3.1.0]hexane compounds as mGluR 2/3 antagonists

A compound of the formula (I) wherein the variables X, X, B, D, Rto Rincluding R, p, y, q, and z, are as defined or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed. 

Opioid receptor antagonists

A selective kappa opioid receptor antagonist useful for treating ethanol use disorder withdrawal and anxiety, and/or depression, or schizophrenia as independent comorbid conditions.

Kappa selective opioid receptor antagonist

A selective kappa opioid receptor antagonist, (S)-3-Fluoro-4-[4-[2-(3,5-dimethylphenyl)pyrrolidin-1-yl-methyl]phenoxy]benzamide or a pharmaceutically acceptable salt thereof, useful for treating ethanol use disorder withdrawal, and anxiety and/or depression, or schizophrenia as independent comorbid conditions.

Compound 5-(2-Methoxy-4-{[2-(tetrahydro-pyran-4-yl)-ethylamino]-methyl}-phenoxy)-pyrazine-2-carboxamide or a pharmaceutically acceptable salt thereof, useful for the treatment of irritable bowel syndrome.

Diaryl ethers as opioid receptor antagonists

Compound 6-(2-fluoro-4-[[2-(tetrahydro-pyran-4-yl)-ethylamino]-methyl]-phenoxy)-nicotinamide, or a pharmaceutically acceptable salt thereof, is useful for the treatment of alcoholism. 

A compound of the formula (I); wherein the variables Xto X, Rto Rincluding R, E, W, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed. 

A compound of the formula I: (I) wherein the variables are as described herein, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixture thereof, formulations and methods of use thereof are disclosed. 

A compound of the formula (I) wherein the variables X1, X2, Rto Rincluding R', j, k, p, y, and z, are as defined or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.

Amino-phenoxymethyl-benzamide opioid receptor antagonists

A compound of the formula (I) wherein the variables Xto X, Rto Rincluding R, E, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed 

Diaryl ethers as opioid receptor antagonist

A compound of the formula (I) wherein the variables X, X, B, D, Rto Rincluding R, p, y, q, and z, are as defined or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed 

Diphenylether amide derivatives as opioid receptor antagonists

A compound of the formula (I) (I) wherein the variables X1 to X6, Ra, Rb, R1 to R7 including R3', E, p, j, y, z, A, B and C are as described or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed 

The present invention relates to muscarinic receptor modulators, specifically, 7-oxo-2-azabicyclo&lsqb;2.2.1&rsqb;heptanes of formula (I) which are useful for the treatment of various diseases and conditions, for example, Alzheimer's disease, glaucoma, psychosis, particularly schizophrenia or schizophreniform conditions, mania, pain, bipolar disorder, depression, sleeping disorders, epilepsy, gastrointestinal motility disorders, urinary incontinence, and cognition enhancement.

7-oxo-2-azabicyclo&lsqb;2.2.1&rsqb;heptanes as selective muscarinic receptor antagonist

Growing community of inventors

Columbus, IN, United States of America

Charles Howard Mitch